latest development

London (UK), Rehovot (IL), 13th September 2023 

Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ).

Vidac Pharma Holding Plc will hold its Annual Shareholders Meeting in person and on-line on Sept 29th at 10am CET and present the Balance Sheet for approval and decide on giving authority to the Board to issue new shares for expected Investors. During the few months of being a public company in both the Hamburg and the Stuttgart Stock Exchange the company succeeded in establishing contact and cooperation with Centroderm which is one of the best specialized dermatologic centers in Germany. We are getting ready for our forthcoming Pre-Phase 3 Clinical trial in Actinic Keratosis, and already ordered Active Pharmaceutical ingredient (API). The Company received biostatistician encouraging analysis of our exploratory Phase 2 in CTCL, a Cutaneous Lymphoma Cancer. Our solid tumors oriented new molecules gave exceptional positive results from the HCS tri-dimensional Cell culture arrays. The Company signed a R&D collaboration with the famous Sheba Hospital for testing these molecules as facilitators for Cancer Immunotherapy together with CART-T treatments. Details on the tenue of the Annual Shareholder meetings are on our site

Rehovot (Israel), London (UK)

About Vidac Pharma: Vidac Pharma Holdings Plc. London, is the holding company of Vidac Pharma Ltd. Rehovot. The Company is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. 


The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.

Vidac Pharma Holding PLC
Dr. Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom


 +972 (0)779300647